Is Albumin a Blood Product or Plasma Derivative?

Albumin is a plasma derivative, not a whole blood product in the traditional sense. It starts as human plasma, the liquid portion of blood, but undergoes extensive industrial fractionation, purification, and viral inactivation steps that transform it into a pharmaceutical product far removed from the bag of red cells or fresh frozen plasma hanging beside a hospital bed. This distinction matters for regulatory oversight, infection risk, religious objections to blood products, and how hospitals manage their supply chains. The line between “blood product” and “plasma derivative” is less intuitive than it sounds, and where albumin falls on that line has real consequences for patients and clinicians.

Where Albumin Comes From

In your body, albumin is the most abundant protein in blood plasma. It helps maintain fluid balance by keeping water inside blood vessels (a function called oncotic pressure), and it acts as a carrier molecule for hormones, fatty acids, bilirubin, and many drugs.¹ When clinicians talk about albumin as something they infuse, they mean a purified solution of this protein extracted from pooled human plasma donations.

The manufacturing process traces back to the early 1940s, when Edwin Cohn at Harvard Medical School was commissioned by the U.S. military to create a stable albumin solution for treating blood loss on the battlefield. Cohn developed an ethanol precipitation method that separated plasma into distinct protein fractions, and albumin was the star product of that effort.² The basic principle still underpins modern manufacturing: by carefully adjusting the concentration of cold ethanol, the pH, and the temperature, different plasma proteins become insoluble at different stages and can be collected separately. At the molecular level, the ethanol dehydrates the protein molecules, allowing them to clump together through attractive forces and drop out of solution.³

Modern commercial fractionation plants pool plasma from thousands of donors and run it through multiple precipitation steps, chromatography columns, and filtration processes. The end product, a 4% or 5% albumin solution (or a more concentrated 20% or 25% version), bears little resemblance to the original plasma. It contains no red cells, no white cells, no platelets, and no clotting factors. That degree of processing is the crux of why albumin is classified differently from whole blood or standard blood components.

The Classification That Matters

In regulatory language, albumin falls under the category of plasma-derived medicinal products. Both the U.S. Food and Drug Administration and the European Medicines Agency regulate albumin manufacturing under frameworks that cover donor selection, plasma testing, and safety measures throughout the production chain.⁴ This puts albumin in the same regulatory family as clotting factor concentrates, intravenous immunoglobulins, and other fractionated plasma products rather than in the group that includes packed red blood cells, platelets, and fresh frozen plasma.

The practical difference is significant. Traditional blood components (red cells, platelets, fresh frozen plasma, cryoprecipitate) are prepared by relatively simple separation of donated blood and then stored with minimal processing. They carry a higher residual risk of transmitting infections and have short shelf lives, sometimes just days. Plasma derivatives like albumin, by contrast, go through industrial-scale purification and dedicated viral inactivation steps. They are manufactured under pharmaceutical Good Manufacturing Practice standards, assigned lot numbers, and distributed more like drugs than like blood bank products.

Hospitals typically manage blood components through their blood bank or transfusion service, while albumin may be stocked by the pharmacy. This administrative split reflects the regulatory distinction and sometimes creates confusion when clinicians order albumin, since the ordering pathway can differ from hospital to hospital.

How Pathogens Are Removed

One of the strongest practical arguments for treating albumin differently from whole blood components is its safety profile regarding infectious agents. The standard viral inactivation step for albumin is pasteurization: heating the solution to 60°C for 10 hours in the presence of stabilizers that protect the albumin protein while destroying viruses.⁵ This process is effective against a broad range of bloodborne viruses, including HIV, hepatitis B, and hepatitis C.

Standard pasteurization is less effective against certain non-enveloped viruses, which have tougher outer shells. Hepatitis A virus is the most clinically relevant example. Research has shown that combining pasteurization with alkaline conditions (raising the pH to around 9.5) substantially improves inactivation of these harder-to-kill viruses.⁶ Even with standard pasteurization alone, hepatitis A inactivation varies depending on the virus strain and the albumin concentration used; higher-concentration albumin solutions (25%) achieve better viral kill than lower-concentration solutions (5%).⁷

Prion diseases, particularly variant Creutzfeldt-Jakob disease (vCJD), represent a different kind of concern because prions are misfolded proteins that resist conventional sterilization. While there have been confirmed cases of vCJD transmission through non-leucocyte-depleted red cell concentrates, there is no reported evidence that fractionated plasma products like albumin have transmitted the disease.⁸ The multiple purification steps in fractionation appear to remove or dilute prion proteins to a degree that whole blood components cannot match. This is one reason the safety record of albumin has been remarkably clean over decades of widespread use, even during eras when blood screening was less sophisticated than it is today.

What Albumin Is Used For

Albumin’s clinical role centers on its ability to expand plasma volume and, in concentrated form, to draw fluid from swollen tissues back into the bloodstream. Its most established uses involve liver disease. In patients with decompensated cirrhosis and ascites, albumin infusions help prevent kidney problems after large-volume paracentesis (draining fluid from the abdomen), treat kidney injury triggered by spontaneous bacterial peritonitis, and manage hepatorenal syndrome. Evidence also supports longer-term albumin administration in these patients to reduce mortality and complications and to ease ongoing management of fluid accumulation.⁹

Beyond liver disease, albumin is used during major surgeries, in burn care, and sometimes during sepsis management. A randomized trial explored whether aggressively targeting a specific serum albumin level with repeated daily infusions of 20% albumin in hospitalized cirrhosis patients would reduce infections, kidney dysfunction, and death, though the benefits of that aggressive approach remained uncertain.¹⁰ The question of exactly when albumin is worth its cost continues to generate debate, because for simple fluid replacement, cheaper alternatives exist.

Albumin Versus Saline in Critical Care

One of the longest-running clinical debates involves whether albumin offers any advantage over plain saline for fluid resuscitation in intensive care. The landmark SAFE trial, a large randomized study of nearly 7,000 ICU patients, compared 4% albumin to normal saline and found essentially identical outcomes. Death rates were virtually the same between the two groups, and there were no meaningful differences in days spent in the ICU, days on mechanical ventilation, or days requiring kidney support.¹¹

The picture in sepsis specifically has been scrutinized further. A systematic review and meta-analysis comparing albumin to crystalloid solutions in patients with septic shock found no clear benefit for albumin in terms of all-cause mortality, 28-day mortality, or 90-day mortality.¹² These findings do not mean albumin is useless in critical care, but they do mean that for the common scenario of simply replacing fluid volume, saline works about as well at a fraction of the cost. Albumin’s advantages tend to show up in specific subpopulations, particularly patients with severe liver disease, where the protein’s oncotic and binding properties address pathology that saline cannot.

The Cost Question

Albumin is expensive compared to crystalloid fluids. A bag of normal saline costs a few dollars; a comparable volume of albumin can cost ten to fifty times as much, depending on the concentration and the country. This price gap makes the clinical decision to use albumin a question of value, not just efficacy. In settings like sepsis resuscitation, where the mortality benefit over saline is marginal at best, economic analyses have produced mixed conclusions. One analysis in sepsis patients found an incremental cost of roughly $1,007 for each additional percentage point improvement in the probability of leaving the ICU alive, with albumin favored only when decision-makers were willing to pay above about $800 per incremental percent.¹³ Another analysis estimated an incremental cost-effectiveness ratio of about $5,500 per life year gained with albumin, and found roughly a coin-flip chance of albumin being cost-effective at one GDP-per-capita threshold.¹⁴

Where albumin’s cost is more clearly justified is in its established liver disease indications. There, no equivalent cheap substitute exists for the specific physiological effects albumin provides. Hospitals that want to manage costs tend to restrict albumin use through formulary controls, requiring documentation of an approved indication before the pharmacy releases it.

Global Supply and Dependence on U.S. Donors

Because albumin is made from human plasma, its supply depends entirely on how much plasma is collected. Many countries lack plasma self-sufficiency and rely on the United States, which supplies roughly 70% of the world’s plasma.¹⁵ The U.S. dominates global collection largely because it permits compensated plasmapheresis, where donors are paid for their time. Most European countries rely on voluntary unpaid donation for whole blood but cannot generate enough plasma through that system alone to meet domestic demand for fractionated products.

This dependence creates vulnerability. Any disruption to U.S. plasma collection, whether from a pandemic, regulatory changes, or shifts in donor behavior, ripples through the global supply of albumin and other plasma derivatives. The scarcity of key plasma-derived medicinal products has been a growing concern, and the pressures on plasma supply have intensified over recent decades.¹⁶ For countries that view dependence on foreign paid donors as ethically or strategically uncomfortable, this supply dynamic adds urgency to the search for alternatives.

Storage Advantages Over Blood Components

One underappreciated difference between albumin and traditional blood components is shelf life. Red blood cells last about 42 days under refrigeration. Platelets last only about five days. Fresh frozen plasma can be stored for a year but requires a freezer. Albumin, by contrast, has a shelf life of roughly one year at room temperature and up to five years when refrigerated at 2 to 8°C.¹⁷ It does not need to be crossmatched to a patient’s blood type, and it requires no special thawing. These logistics make albumin far easier to stockpile and distribute than standard blood products, which is partly why it was such an attractive battlefield product when Cohn first developed it.

Recombinant Albumin and the Push Away From Donor Plasma

The dependence on human donors has driven decades of research into making albumin without plasma. Recombinant human serum albumin (rHSA) has been produced in several expression systems, including yeast and, more recently, rice plants. Mass spectrometry and protein sequencing have confirmed that recombinant albumin produced in rice is structurally identical to plasma-derived albumin.¹⁸

The clinical evidence has also begun to catch up with the bench science. A randomized, double-blind trial in patients with decompensated liver cirrhosis compared rice-derived recombinant human albumin (OsrHSA) to plasma-derived albumin and found that the recombinant version was non-inferior: about 76% of patients in both groups met the primary outcome, with no significant differences in secondary outcomes and no drug-related serious adverse events.¹⁹ If recombinant albumin can be manufactured at scale with consistent quality and competitive pricing, it could eventually decouple the albumin supply from the vagaries of human plasma donation.

One challenge that remains is consistency. Different expression systems, and even different suppliers using the same system, can introduce chemical modifications to the protein that affect its stability and potentially its immunogenicity. Recombinant albumins produced in rice have shown particularly high variability in these modifications compared to plasma-derived albumin or yeast-expressed versions.²⁰ Getting this variability under control is essential before recombinant albumin can replace plasma-derived albumin on a broad clinical scale.

Religious and Ethical Dimensions

The classification of albumin as a plasma derivative rather than a blood component carries weight in religious contexts where blood transfusion is prohibited or restricted. Jehovah’s Witnesses, for example, generally decline transfusion of whole blood and its primary components (red cells, white cells, platelets, and plasma). However, the stance on fractionated products like albumin, immunoglobulins, and clotting factors is left to individual conscience within the faith. Some Witnesses will accept albumin; others will not. The key distinction from their perspective is that albumin is a fraction of a fraction, extracted and processed beyond what they consider a primary blood component.

In Islamic jurisprudence, opinions similarly hinge on the degree of transformation the original substance has undergone. Because albumin is highly purified and pasteurized, many scholars consider it permissible (halal) on the grounds that it has been sufficiently transformed from its original state. Clinicians treating patients from these communities need to understand that “blood product” is not a monolithic category for everyone, and the specific manufacturing pathway of albumin often places it in a gray zone that patients navigate individually.

Albumin in Veterinary Medicine

The classification question takes on a different twist in veterinary practice. Dogs and cats develop low albumin levels from liver disease, kidney disease, or severe illness, just as humans do. Species-specific albumin products are the ideal treatment: canine serum albumin for dogs, for instance. But availability and cost are major barriers, which has led some veterinarians to use human serum albumin or bovine serum albumin as substitutes. This practice carries real risk, because the immune system of a dog or cat may recognize a foreign-species protein as a threat, triggering potentially fatal allergic reactions.²¹

Even with species-matched albumin, adverse reactions are not trivial. A retrospective study of lyophilized canine albumin use in dogs found that transfusion reactions occurred in about one in five transfusion events, with reactions ranging from mild fevers to life-threatening episodes.²² The veterinary situation highlights how much the safety of commercial human albumin depends on the decades of refinement in manufacturing and viral inactivation that the human product has benefited from. Veterinary albumin products are newer, less standardized, and produced in far smaller volumes, all of which affect their safety profile and classification status in animal medicine.